La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Modular Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Modular Medical..

Modular Medical (NASDAQ:MODD) Azioni, Catena delle Opzioni

Modular Medical

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

Modular Medical Inc

TD Cowen analyst Jason Gabelman maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Buy and raises the price target from $202 to $242.

News

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Cheniere Energy, Raises Price Target to $242

WIIM

UCloudlink Group shares are trading lower after the company reported worse-than-expected Q3 sales results.

Office Properties Income Trust shares are trading higher. The company announced a debt refinancing plan for up to $340 million in senior unsecured notes

B. Riley Securities analyst Naved Khan maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Buy and raises the price target from $24 to $27.

ACVA

B. Riley Securities Maintains Buy on ACV Auctions, Raises Price Target to $27

Raymond James analyst Savanthi Syth reiterates Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Market Perform.

Reiteration

EVTL

Raymond James Reiterates Market Perform on Vertical Aerospace

B. Riley Securities analyst Hal Goetsch maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Buy and raises the price target from $110 to $150.

FOUR

B. Riley Securities Maintains Buy on Shift4 Payments, Raises Price Target to $150

B. Riley Securities analyst Craig Kennison maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and raises the price target from $61 to $85.

SMTC

B. Riley Securities Maintains Buy on Semtech, Raises Price Target to $85

Real Good Food Company shares are trading higher. The company requested an extension regarding its Nasdaq delinquency notice.

<h3>The partnership will connect advertisers in a privacy-protective manner to SMB audiences to create more accurate and better-performing B2B marketing campaigns</h3>
REDWOOD CITY, Calif – November 26, 2024&nbsp;– PubMatic, an independent technology company delivering digital advertising's supply chain of the future, announced a new strategic partnership with Intuit's SMB MediaLabs that will make rich first-party SMB audiences available in PubMatic's self-service Convert platform for commerce media. This collaboration will enable publishers and advertisers to access unparalleled data-led targeting capabilities, significantly enhancing B2B marketing campaign performance and accuracy.
Intuit's SMB MediaLabs is a first-of-its-kind media network focused solely on small and medium-sized businesses. It reaches an audience of millions of small and medium businesses leveraging 36 million identifiers through Intuit QuickBooks, while keeping the underlying customer data secure on Intuit's platform. SMB MediaLabs launched in July 2023 as a managed service via insertion orders. Now, in partnership with PubMatic, enterprise-level and large holding company buyers and publishers offering premium, brand-safe inventory across CTV, video, mobile and more will be able to connect marketers to this attractive audience-segment through PubMatic. Plus, SMB MediaLabs advertisers will be able to connect to these data segments directly via PubMatic's self-service Convert platform, a flexible, integrated white-label tech solution for retailers and marketplaces.

INTU

PUBM

Pubmatic Forges Partnership With Intuit SMB Medialabs To Advance B2B Advertising With Privacy-Protective Solutions

B. Riley Securities analyst Eric Wold downgrades Brunswick (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>) from Buy to Neutral and lowers the price target from $95 to $88.

Downgrades

B. Riley Securities Downgrades Brunswick to Neutral, Lowers Price Target to $88

VEEA

Veea shares are trading higher after the company announced partnership  based on MARQUEE's patented SMARTCELL platform. Under the initiative, Veea's decentralized physical infrastructure network will accelerate the introduction of MEC solutions with Edge AI as an extension of the cellular network inftrascuture.

On Monday, the Centers for Medicare &amp; Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Included was a final decision related to CMS pricing for Exact Sciences Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus, a second-generation test that received FDA <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">approval in October</a>.
William Blair writes that the <a target="_blank" href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings" rel="noreferrer noopener">determinations</a> effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a>
The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.
The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).
This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.
The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.
From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair&#8217;s estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42177702/exact-sciences-advances-breast-cancer-care-with-the-oncotype-dx-test-and-genomic-profiling-researc" rel="noreferrer noopener">scheduled next month</a>.
Price Action: EXAS stock is up 7.60% at $59.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Equities

Health Care

Movers

Trading Ideas

General

EXAS

Why Is Exact Sciences Stock Trading Higher On Monday?

CIMG Shares Resume Trade

Truist Securities analyst Keith Hughes downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Buy to Hold and lowers the price target from $60 to $52.5.

Truist Securities Downgrades Summit Materials to Hold, Lowers Price Target to $52.5

TD Cowen analyst Ryan Langston maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Buy and lowers the price target from $275 to $251.

TD Cowen Maintains Buy on Universal Health Servs, Lowers Price Target to $251

Live On CNBC, Bill Baruch Announces Sold Chubb

Raymond James analyst David Long upgrades Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) from Market Perform to Strong Buy and announces $28 price target.

Upgrades

Raymond James Upgrades Old National to Strong Buy, Announces $28 Price Target

Shares of Maxeon Solar Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) are volatile Tuesday after the company announced a significant restructuring of its business operations. Here&#8217;s <a href="https://www.benzinga.com/quote/MAXN/news">what you need to know.</a>
What To Know: Maxeon Solar announced plans to focus exclusively on the U.S. market, citing its established presence and a planned local manufacturing facility as key elements for growth.
As part of the restructuring, Maxeon has signed a five-year lease for a facility in Albuquerque, New Mexico. The company aims to begin solar panel production at this site in 2026 with an initial planned capacity of 2 gigawatts. This marks the company&#8217;s first step in a broader initiative to establish a domestic solar panel supply chain.
&#8220;As Maxeon intensifies its focus on the U.S. market, our priority is to further expand our growing residential and commercial partner network and support our well-established base of utility-scale customers,&#8221; said George Guo, Maxeon&#8217;s CEO.
See Also: <a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs &#8216;As A Weapon&#8217;</a>
In a move to exit other international markets, Maxeon has reached agreements in principle with TCL Technology Group, its majority shareholder, to sell its sales and marketing operations in Europe, Asia-Pacific and Latin America. TCL plans to integrate the operations into a new unit called TCL SunPower International, which will also acquire Maxeon's manufacturing operations in the Philippines.
Following the transactions, Maxeon will focus solely on the U.S. residential, commercial and utility-scale solar markets. The restructuring aligns with the company&#8217;s strategy to strengthen its U.S. operations and prioritize domestic solar supply chain development.
The agreements between Maxeon and TCL are expected to be finalized by the end of 2024, with the Albuquerque project contingent on securing financing.
&#8220;This strategic re-focusing of our business is designed to keep us closer and more attuned to the needs of our U.S. customer base, allowing us to leverage Maxeon&#8217;s deep experience and top-tier reputation for product innovation and quality that are a result of almost 40 years of technology leadership and investments in intellectual property,&#8221; Guo added.
MAXN Price Action: <a href="http://benzinga.com/quote/maxn">Maxeon Solar shares</a> initially traded up above $10 per share before reversing course and turning negative. The stock was down 3.76% at $7.68 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-1024x553.png" alt="" class="wp-image-665701" style="width:455px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-1024x553.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42193222/orange-taps-openai-meta-to-create-ai-that-speaks-african-languages">Meta, OpenAI, Orange Join Forces To Build AI Models For African Languages</a></li>
</ul>
Photo by Nuno Marques on Unsplash..

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

What's Going On With Maxeon Solar Technologies Stock Today?

Billionaire Elon Musk surprised many people when he bought social media platform Twitter in 2022, and he could be back with another media acquisition in 2025. In a post, he asked about the price of Comcast Corporation&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) cable assets, ahead of <a href="https://www.benzinga.com/news/global/24/11/42081224/comcast-plans-major-cable-networks-spinoff-msnbc-and-cnbc-to-form-new-public-company-report">a planned spinoff.</a>
What Happened: Musk spent $44 billion to acquire Twitter, now known as X, <a href="https://www.benzinga.com/news/23/04/31810229/elon-musk-bought-twitter-1-year-ago-a-look-back-at-whats-happened-since-and-what-could-be-next">back in 2022</a>. The move added to the portfolio of companies owned or controlled by the world's richest man.
Musk could have his eyes set on the cable assets of Comcast Corporation being spun off, which include MSNBC, CNBC, USA, Oxygen, E!, Syfy and Golf Channel. Comcast will keep ownership of the NBC broadcast network, Bravo, NBC Sports, Peacock streaming platform and Universal theme parks.
While Comcast has not placed MSNBC or other assets for sale, choosing instead to spin them off as a separate company, Musk has expressed interest either jokingly or as a foreshadowing of an eventual purchase.
"How much does it cost?" Musk <a href="https://x.com/elonmusk/status/1860037420710080687">tweeted </a>in reply to a post from Donald Trump Jr. saying he had "the funniest idea ever."
Trump Jr. shared a post suggesting that Comcast was looking for a buyer of MSNBC.
While Musk has spoken ill of the "mainstream media" for many years, a purchase of MSNBC or the cable assets from Comcast wouldn't be a huge surprise at this point, given his past purchase of Twitter.
Musk <a href="https://x.com/redletterdave/status/1518585718012059648">posted </a>that he loved Twitter on Dec. 21, 2017, which prompted a user to say "you should buy it then." Musk responded "how much is it" and that post preceded Musk's eventual acquisition of the company.
The billionaire has often said "the most entertaining outcome is the most likely" and an acquisition of MSNBC would certainly be entertaining.
Prediction market Polymarket has a betting market <a href="https://polymarket.com/event/will-elon-musk-buy-msnbc-before-april-2025">open </a>for "Will Elon Musk buy MSNBC?" The market, which has around $520,000 wagered, currently shows a 15% chance that Musk buys MSNBC. The market, which opened for trading on Nov. 22, hit a high of 19% on Nov. 23. The prediction market shows a low probability of Musk announcing an acquisition.
On Polymarket, users deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). Winning wagers cash out at $1 per contract.
The market will resolve as &#8220;Yes&#8221; if Musk or a Musk-controlled entity announced a plan to acquire MSNBC by March 31, 2025 whether the acquisition has been completed.
<ul>
<li>You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/24/11/42144099/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-44">check out five stocks flying under the radar that deserve your attention.</a></li>
</ul>
Is Musk Serious?: The big question on everyone's mind is whether Musk is serious. Buying MSNBC would add to the billionaire's portfolio of companies and also increase his workload, which comes as he is set to take on a government role co-leading the Department of Government Efficiency.
Musk currently owns or leads X, SpaceX, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), xAI, The Boring Company, Neuralink and more. While some of these companies count on other individuals as CEO or COO to offset Musk's other time commitments, there likely aren't enough hours in the day for Musk to make an impact at all these companies already on the daily.
"My workload went up from 70 to 80 hours a week to probably 120," Musk said <a href="https://www.benzinga.com/news/22/11/29582707/elon-musks-life-after-twitter-acquisition-i-wake-up-work-go-to-sleep-work-do-that-7-days-a-week-1">after buying Twitter.</a> "Go to sleep, I wake up, work, go to sleep, work, do that 7 days a week."
While Musk is a known workaholic and likely would love the challenge of adding another company to the mix, Tesla shareholders might not love the thought.
As a publicly traded company, Tesla is one of Musk&#8217;s top priorities and frequently faces intense scrutiny for missed milestones and performance targets. If Musk were to devote more time to leading MSNBC after a potential acquisition, it would likely raise concerns among investors and analysts.
Musk is worth $348 billion according to <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>, making him the richest person in the world. Another key question would be how much cash Musk readily has available or if he would need to borrow against his key holdings or sell Tesla stock to complete the acquisition.
The billionaire<a href="https://www.benzinga.com/m-a/22/10/29444090/musk-hasnt-sold-more-tesla-shares-to-fund-44b-twitter-deal-could-overhang-be-gone"> sold Tesla shares </a>in 2022 to help fund the Twitter acquisition, a move some analysts referred to as an overhang on Tesla stock. Tesla stock was down 65% in 2022, marking the worst year since the company went public and one of only two years the stock has been down since going public in 2010.
Why It's Important: A report from <a href="https://www.cnn.com/2024/11/25/media/elon-musk-msnbc-spinoff-cable/index.html">CNN </a>says that at least one billionaire has reached out to express interest in buying MSNBC and it wasn't Musk.
Comcast has not indicated that MSNBC or its other assets are for sale. With plans already in motion for a tax-free spinoff of a new company to shareholders, it would likely require an exceptionally compelling offer to persuade the board or shareholders to consider an alternative course.
While one unnamed billionaire is interested, another told CNN he has no interest.
"I don't think there is anything anyone can do to change the impact of linear TV news. So the answer is no," Mark Cuban told CNN.
CMCSA Price Action: Comcast stock is down 1.5% to $42.54 on Tuesday, versus a 52-week trading range of $36.43 to $47.11. The stocks' year-to-date and five-year returns of negative 1.1% and negative 2.2%, respectively, have greatly trailed the overall market, with the SPDR S&amp;P 500 ETF Trust up 26.4% year-to-date and up 90.1% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41142828/elon-musk-bought-x-for-44b-now-fidelity-values-social-media-network-below-10b">Elon Musk Bought X For $44B, Now Fidelity Values Social Media Network Below $10B</a></li>
</ul>
Photo: Shutterstock

Entertainment

Media

$ETH

$MATIC

$USDC

CMCSA

TSLA

Will Elon Musk Buy MSNBC? Recent News Parallels Twitter Acquisition, But Polymarket Shows Low Odds Of A Deal

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $65 to $75.

BTIG Maintains Buy on Exact Sciences, Raises Price Target to $75

Modular Medical initiates transfer of manufacturing operations to Phillips Medisize

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Modular Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/modd-stock-quote/">MODD</a>) just reported results for the first quarter of 2025.<ul><li>Modular Medical reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/modd-stock-earnings-modular-medical-for-q1-of-2025/">MODD Stock Earnings: Modular Medical Beats EPS for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MODD Stock Earnings: Modular Medical Beats EPS for Q1 2025

Modular Medical (MODD) has provided an announcement. Modular Medical, Inc. introduced a Bonus Program to motivate its employees with stock options ...

Modular Medical Incentivizes FDA Milestones with Stock Options

Modular Medical reports issuance of U.S. patent covering key aspects of core pumping technology

Modular Medical (MODD) is a Gold sponsor of the upcoming, first annual Achieving Diabetes Equity in Practice Today Conference taking place at the C...

Modular Medical sponsors inaugural ADEPT conference

Modular Medical announces proposed public offering

Modular Medical (MODD) announced that it has commenced an underwritten public offering of shares of its common stock. Titan Partners Group, a divis...

Modular Medical announces common stock offering, no amount given

The deal priced below last closing price of $1.94. Titan Partners is acting as sole book running manager for the offering. Published first on TheFl...

Modular Medical 5.45M share Spot Secondary priced at $1.50

Modular Medical drops 8%, prices $8.2M stock

Modular Medical drops 8%, prices $8.2M stock offering

MODD

Press Releases

Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology

Events

Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH)

Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

Registration Is Now Open For Tribe Public's Webinar Event "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing" Featuring Modular Medical CEO On Monday, November 11, 2024

Modular Medical Proudly Sponsors the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference

Offerings

Modular Medical Announces Proposed Public Offering

Modular Medical Announces Pricing of $8.2 Million Public Offering

ACXP

CRDL

DBVT

LPTH

NVDA

PRSO

SGTM

SWISF

TSX:CRDL

VRAX

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Modular Medical

Modular Medical (MODD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO